<DOC>
	<DOCNO>NCT00354458</DOCNO>
	<brief_summary>The study conduct examine whether KW-3902IV result great improvement sign symptom heart failure , less treatment failure standard therapy , add IV loop diuretic subject acute heart failure syndrome renal impairment .</brief_summary>
	<brief_title>PROTECT-2 : A Study Selective A1 Adenosine Receptor Antagonist KW-3902 Patients Hospitalized With Acute HF Volume Overload Assess Treatment Effect Congestion Renal Function</brief_title>
	<detailed_description>Loop diuretic generally first line therapy patient hospitalize acute heart failure syndrome ( AHFS ) . Their use far exceed vasoactive agent . Tubuloglomerular feedback ( TGF ) body 's compensatory response avoid excess fluid loss , activate elevate sodium concentration distal tubule detect . TGF propose contribute factor observe diuretic resistance occur patient heart failure . Higher dos diuretic require overcome decrease natriuresis reduce RBF induce TGF . Ultimately , action create vicious cycle worsen renal function diminish diuretic effectiveness . The primary pharmacologic rationale use KW-3902 subject AHFS mechanism action adenosine A1 receptor antagonist . TGF promote release adenosine , adenosine binding A1 receptor cause vasoconstriction afferent arteriole , decrease RBF , enhance sodium reabsorption proximal tubule . This action result decrease GFR , diminish renal function , sodium water retention . Blocking adenosine A1 receptor via selective adenosine receptor antagonist may limit sodium reabsorption proximal tubule without trigger TGF . It promote vasodilation afferent arteriole glomerulus , thus , strategy offer potential overcome diuretic resistance enhance diuretic responsiveness . It may also reduce need increase diuretic dos associate bad outcome . The objective study evaluate effect KW-3902IV addition intravenous ( IV ) loop diuretic ( furosemide ) heart failure sign symptom , renal function , safety subject hospitalize AHFS , volume overload , renal impairment , estimate compare within-trial medical resource utilization direct medical cost patient treat KW-3902IV versus placebo .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Rolofylline</mesh_term>
	<mesh_term>Purinergic P1 Receptor Antagonists</mesh_term>
	<criteria>1 . History heart failure least 14 day duration diuretic therapy prescribe 2 . Hospitalized acute heart failure syndrome require IV diuretic therapy . 3 . Impaired renal function 1 . Acute contrast induce nephropathy 2 . Ongoing plan IV therapy heart failure positive inotropic agent , vasopressor , vasodilator , mechanical support exception IV nitrate 3 . BNP &lt; 500 pg/mL NTproBNP &lt; 2000 pg/mL 4 . Ongoing plan treatment ultrafiltration , hemofiltration , dialysis 5 . Severe pulmonary disease 6 . Significant stenotic valvular disease 7 . Heart transplant recipient admit cardiac transplantation 8 . Clinical evidence acute coronary syndrome 2 week prior screen 9 . Heart failure due significant arrhythmias 10 . Acute myocarditis hypertrophic obstructive , restrictive , constrictive cardiomyopathy . 11 . Known hepatic impairment 12 . Noncardiac pulmonary edema , include suspect sepsis 13 . Allergy soybean oil egg 14 . History seizure 15 . Stroke within 2 year 16 . History current brain tumor etiology 17 . Brain surgery within 2 year 18 . Encephalitis/meningitis within 2 year 19 . History penetrate head trauma 20 . Closed head injury loss consciousness ( LOC ) 30 minute within 2 year 21 . History , risk , alcohol withdrawal seizures 22 . Advanced Alzheimer 's disease 23 . Advanced multiple sclerosis 24 . Hgb &lt; 8 g/dL , Hct &lt; 25 % , need blood transfusion 25 . Previous exposure KW3902</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>heart failure</keyword>
	<keyword>diuretic</keyword>
	<keyword>renal impairment</keyword>
	<keyword>renal function</keyword>
</DOC>